Elanco Animal Health Incorporated (ELAN) on Thursday said it has received conditional approval from the U.S. Food and Drug Administration (FDA) for Credelio Quattro CA1 for the treatment of infestations caused by New World screwworm larvae in dogs.
The conditional approval was based on a study evaluating the efficacy of lotilaner, the active ingredient in Credelio Quattro CA1, against New World screwworm. Published in Parasites & Vectors, the study found that oral administration of lotilaner at the minimum recommended dosage was 100% effective against Cochliomyia hominivorax larvae within 24 hours in naturally infested dogs.
According to the U.S. Department of Agriculture, 14 cases of New World screwworm have been reported within 400 miles of the U.S.-Mexico border, all linked to cattle movement.
ELAN shares were up more than 2% in pre-market after closing at $22,08, down 1.82%.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.